New RNA upgrades make prime gene editing highly efficient

Summary

Prime editing is a highly precise genetic tool that allows scientists to rewrite DNA without making dangerous double-strand breaks in the genetic code. To do this, the system relies on a guide molecule made of RNA, which acts like a biological GPS to find the exact spot in the genome that needs fixing. However, these RNA guides are fragile and can break down inside cells before they finish the job. To protect them, scientists attach tiny stabilizing structures, known as motifs, to the end of the RNA guide.

To find the best possible stabilizers, researchers developed a new high-throughput testing system called PE-PRISM. This tool allowed them to rapidly screen 2,858 different RNA motifs inside human cells. Through multiple rounds of testing and optimization, the research team identified three engineered winners named tevo2.0, eHAV, and eSBRMV1-A.

When put to the test, these newly upgraded motifs completely outperformed the current standard stabilizer. In experiments designed to correct hundreds of disease-associated genetic mutations, the top new motifs proved more efficient than the older version over 90 percent of the time. The researchers successfully used these stabilized guides to correct mutations in human cells as well as inside the brains and livers of living mice.

Why it matters.

Improving the efficiency of prime editing is a crucial step for turning this breakthrough technology into a reliable medical treatment. By making the RNA guides more stable, scientists can successfully correct a wider range of genetic diseases with a much higher success rate. The fact that these new motifs worked so well in the brains and livers of living mice suggests that the upgraded system is powerful enough to tackle complex diseases in whole organisms, rather than just isolated cells in a laboratory.

Despite these exciting results, the research is still in its early preclinical stages. Because the current experiments rely entirely on cellular and mouse models, the upgraded prime-editing system will require extensive testing and safety validation before it can be used in human clinical trials. Nevertheless, these protective RNA designs bring the medical field an important step closer to safe, highly efficient gene therapies.

From the source

The story in numbers.

RNA motifs evaluated: 2,858
Pathogenic ClinVar variants screened: 847
Edits showing improved efficiency over tevopreQ1: >90%

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

First inside-the-body CRISPR gene therapy heads to the FDA

Intellia Therapeutics is making medical history as it seeks approval from the US Food and Drug Administration for a groundbreaking genetic treatment. The drug, called lonvoguran ziclumeran or lonvo-z, is the first CRISPR-based gene therapy designed to work "in vivo," meaning the genetic editing happens directly inside the human body. CRISPR is a biological tool that allows scientists to make precise changes to DNA. Intellia is using this technology to treat hereditary angioedema, a genetic condition that causes severe and unpredictable swelling attacks. The company recently completed a Phase 3 clinical trial, which is the final testing step before seeking regulatory approval. In the study, a single dose of lonvo-z reduced swelling attacks by 87 percent compared to a placebo over a six-month period. Even more strikingly, 62 percent of the patients who received the treatment had absolutely no attacks during those six months and were able to completely stop taking their usual preventative medications. While these numbers are highly encouraging, the research does come with a few early caveats. The trial was relatively small, involving a total of 80 patients, with 52 receiving the actual therapy and 28 given a placebo. Additionally, the currently reported results only track the patients for six months. Researchers will need to monitor these individuals for a longer period to confirm that the single dose continues to work safely and effectively over time.

Nature Biotechnology2 min read

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News1 min read

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN1 min read

Follow your curiosity.

New RNA upgrades make prime gene editing highly efficient

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

A little science goes a long way.